Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some investors and analysts now believe we are in an AI bubble ready to burst. Even if that's not the case, it's worth considering stocks in other industries that could offer excellent returns. Take Viking Therapeutics (VKTX 1.00%), a biotech company looking to disrupt a fast-growing...
Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some investors and analysts now believe we are in an AI bubble ready to burst. Even if that's not the case, it's worth considering stocks in other industries that could offer excellent returns. Take Viking Therapeutics (VKTX 1.00%), a biotech company looking to disrupt a fast-growing market. Analysts believe this drugmaker is severely undervalued: Viking Therapeutics' average price target of $92.72 (according to Yahoo! Finance) implies an upside of about 181% from its current levels. Should investors purchase shares of Viking Therapeutics right now? The next 18 months could be decisive Viking Therapeutics is developing therapies for chronic weight management. Given recent breakthroughs in this area -- and the fact that obesity is a serious, highly prevalent condition that is also linked to many others -- the weight-loss market is growing rapidly and will continue to do so well into the next decade. Naturally, this field is dominated by large and prominent pharmaceutical leaders, with many others looking to join the party. Viking Therapeutics is a fairly small player in the game, but it does have a somewhat realistic shot at carving a niche. The company's leading candidate, VK2735, is undergoing pivotal clinical trials, including one in adults with obesity and diabetes and another in obese patients without diabetes. Both will measure weight loss over 78 weeks. We should see results from these studies next year. Viking Therapeutics is also developing an oral version of VK2735, which it expects to advance to phase 3 studies in the third quarter. Expand NASDAQ : VKTX Viking Therapeutics Today's Change ( -1.00 %) $ -0.33 Current Price $ 32.65 Key Data Points Market Cap $3.8B Day's Range $ 32.54 - $ 33.59 52wk Range $ 18.92 - $ 43.15 Volume 11K Avg Vol 3M What's your risk tolerance? What would allow Viking Therapeutics to match Wall Street's average price ta...
Key Points Viking Therapeutics' leading candidate should complete some ongoing phase 3 studies next year. The stock might soar, depending on how strong the data is. The Street's optimism must be weighed against the risk Viking Therapeutics carries. 10 stocks we like better than Viking Therapeutics › Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the pas...
Key Points Viking Therapeutics' leading candidate should complete some ongoing phase 3 studies next year. The stock might soar, depending on how strong the data is. The Street's optimism must be weighed against the risk Viking Therapeutics carries. 10 stocks we like better than Viking Therapeutics › Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some investors and analysts now believe we are in an AI bubble ready to burst. Even if that's not the case, it's worth considering stocks in other industries that could offer excellent returns. Take Viking Therapeutics (NASDAQ: VKTX), a biotech company looking to disrupt a fast-growing market. Analysts believe this drugmaker is severely undervalued: Viking Therapeutics' average price target of $92.72 (according to Yahoo! Finance) implies an upside of about 181% from its current levels. Should investors purchase shares of Viking Therapeutics right now? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The next 18 months could be decisive Viking Therapeutics is developing therapies for chronic weight management. Given recent breakthroughs in this area -- and the fact that obesity is a serious, highly prevalent condition that is also linked to many others -- the weight-loss market is growing rapidly and will continue to do so well into the next decade. Naturally, this field is dominated by large and prominent pharmaceutical leaders, with many others looking to join the party. Viking Therapeutics is a fairly small player in the game, but it does have a somewhat realistic shot at carving a niche. The company's leading candidate, VK2735, is undergoing pivotal clinical trials, including one in adults with obesity and diabetes and another in obese patients without diabetes. Both will measure weight...
Trump Cabinet Members Allegedly Buying Nuclear Bunkers Via Modernity.news, The Iran conflict has ignited a massive surge in demand for nuclear-proof bunkers across America , with even top Trump administration officials securing their own underground fortresses amid whispers of World War Three. As The Telegraph reports, Ron Hubbard, owner of Atlas Survival Shelters, reports being “inundated with ca...
Trump Cabinet Members Allegedly Buying Nuclear Bunkers Via Modernity.news, The Iran conflict has ignited a massive surge in demand for nuclear-proof bunkers across America , with even top Trump administration officials securing their own underground fortresses amid whispers of World War Three. As The Telegraph reports, Ron Hubbard, owner of Atlas Survival Shelters, reports being “inundated with calls” since the conflict erupted, with enquiries spiking “tenfold.” The Texas-based company, which builds everything from $20,000 basic shelters to multimillion-dollar compounds, is reaping a harvest from the heightened tensions. Hubbard revealed that two senior Trump Cabinet members are new customers. “One of them texted me yesterday, asking me: ‘When will my bunker be ready?’” he said. These bunkers boast hardened steel construction, armoured blast doors, air purification systems, and luxuries like cinemas, pools, and gun ranges—designed to withstand drone strikes or worse. Yet Hubbard is blunt about limits: “No bunker in the world is designed to withstand a bunker buster from an American bomber. I’m sorry you just can’t make a bunker strong enough.” He added: “If the Americans want you dead, you’re dead. I don’t think any bunker in the world can protect you from an American that wants to kill you.” The boom extends globally, with Hubbard’s new Dubai office fielding urgent requests after Iranian missiles hit the city. “They thought they’d never see bombs fall. But now [they’re getting the s— bombed out of them],” he noted of local clients. Atlas averaged $2 million in monthly sales this year but expects $50 million next month. “Bunker building is like being a farmer. When it’s time for harvest, you have to reap all you can,” Hubbard explained. “Now that they’ve been bombed, they’re all going to want shelters. It’s just a fact of life.” Hubbard has built for tech moguls like Mark Zuckerberg and even Andrew Tate, underscoring how elites are hedging against chaos. Tyler Durde...
Micron Technology (NASDAQ:MU - Get Free Report) had its price target raised by equities research analysts at Susquehanna from $345.00 to $525.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a "positive" rating on the semiconductor manufacturer's stock. Susquehanna's price target would suggest a potential upside of 45.43% from the stock's p...
Micron Technology (NASDAQ:MU - Get Free Report) had its price target raised by equities research analysts at Susquehanna from $345.00 to $525.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a "positive" rating on the semiconductor manufacturer's stock. Susquehanna's price target would suggest a potential upside of 45.43% from the stock's previous close. Several other equities analysts have also issued reports on the company. Morgan Stanley raised their price objective on Micron Technology from $350.00 to $450.00 and gave the stock an "overweight" rating in a report on Wednesday, February 11th. Piper Sandler raised their price target on Micron Technology from $275.00 to $400.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 7th. Mizuho lifted their price target on Micron Technology from $390.00 to $480.00 and gave the stock an "outperform" rating in a research report on Tuesday, January 27th. Rosenblatt Securities reiterated a "buy" rating and issued a $500.00 price objective on shares of Micron Technology in a research note on Tuesday, January 20th. Finally, Wedbush set a $320.00 price objective on Micron Technology in a report on Thursday, December 18th. Six investment analysts have rated the stock with a Strong Buy rating, twenty-nine have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $379.59. Get Micron Technology alerts: Sign Up Read Our Latest Analysis on MU Micron Technology Stock Down 2.5% Shares of MU traded down $9.30 during midday trading on Monday, hitting $361.00. The company had a trading volume of 7,218,095 shares, compared to its average volume of 35,418,762. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.78 and a current ratio of 2.46. The company's 50-day simple moving average is $379.98 and...
Michael M. Santiago/Getty Images News As broader markets grapple with geopolitical uncertainty, oil prices above $100 per barrel, and renewed concerns over global logistics disruptions due to Strait of Hormuz tensions, investors are likely watching out for pockets of stability. Here, we are scanning the healthcare sector for reliable dividend payers. Below is a list of healthcare companies current...
Michael M. Santiago/Getty Images News As broader markets grapple with geopolitical uncertainty, oil prices above $100 per barrel, and renewed concerns over global logistics disruptions due to Strait of Hormuz tensions, investors are likely watching out for pockets of stability. Here, we are scanning the healthcare sector for reliable dividend payers. Below is a list of healthcare companies currently offering some of the highest dividend yields in the sector. Oramed Pharmaceuticals ( ORMP ) - Dividend yield - 7.61%. Embecta ( EMBC ) - Dividend yield - 6.62%. Pfizer ( PFE ) - Dividend yield - 6.36%. DENTSPLY SIRONA ( XRAY ) - Dividend yield - 5.02%. National Research ( NRC ) - Dividend yield - 4.39%. Bristol-Myers Squibb ( BMY ) - Dividend yield - 4.18%. CVS Health ( CVS ) - Dividend yield - 3.41%. Viatris ( VTRS ) - Dividend yield - 3.39%. UnitedHealth ( UNH ) - Dividend yield - 3.09%. Abbvie ( ABBV ) - Dividend yield - 3.01%. More on healthcare stocks The Scotts Miracle-Gro Company (SMG) Presents at 47th Annual Raymond James Institutional Investor Conference - Slideshow CVS Health: Stop Catastrophizing, Start Believing - Here's Why Pfizer: Obesity Hype And Vaccine Policy Shocks AbbVie sees promising early-stage data for weight loss asset ABBV-295 Bristol Myers cancer drug meets main goal in late-stage study
In early trading on Monday, shares of Procter & Gamble topped the list of the day's best performing Dow Jones Industrial Average components, trading up 0.7%. Year to date, Procter & Gamble registers a 7.9% gain. And the worst performing Dow component thus far on the day is Cisco Systems, trading down 2.9%. Cisco Systems is lower by about 0.9% looking at the year to date performance. Two other comp...
In early trading on Monday, shares of Procter & Gamble topped the list of the day's best performing Dow Jones Industrial Average components, trading up 0.7%. Year to date, Procter & Gamble registers a 7.9% gain. And the worst performing Dow component thus far on the day is Cisco Systems, trading down 2.9%. Cisco Systems is lower by about 0.9% looking at the year to date performance. Two other components making moves today are Home Depot, trading down 2.5%, and Johnson & Johnson, trading up 0.4% on the day. VIDEO: Dow Movers: CSCO, PG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
With global markets facing geopolitical uncertainty, oil prices above $100 a barrel, and fresh concerns over logistics disruptions linked to tensions around the Strait of Hormuz, investors seek more stable assets. Here, we are scanning the real estate sector for reliable dividend payers. Below is a list of real estate companies currently offering some of the highest dividend yields in the sector. ...
With global markets facing geopolitical uncertainty, oil prices above $100 a barrel, and fresh concerns over logistics disruptions linked to tensions around the Strait of Hormuz, investors seek more stable assets. Here, we are scanning the real estate sector for reliable dividend payers. Below is a list of real estate companies currently offering some of the highest dividend yields in the sector. Innovative Industrial Properties ( IIPR ), Dividend Yield: 13.98% NexPoint Diversified Real Estate Trust ( NXDT ), Dividend Yield: 13.07% Clipper Realty (CLPR ), Dividend Yield: 12.18% Community Healthcare Trust ( CHCT ), Dividend Yield: 11.46% NewLake Capital Partners ( NLCP ), Dividend Yield: 11.13% The RMR Group ( RMR ), Dividend Yield: 10.52% Brandywine Realty Trust ( BDN ), Dividend Yield: 10.46% Millrose Properties ( MRP ), Dividend yield 10.08%. Gladstone Commercial ( GOOD ), Dividend yield 9.71%. More on real estate stocks NewLake Capital Partners: This Double-Digit Yield Cannabis REIT Is Just Getting Started NewLake Capital Partners: Resilient Dividends, Healthy Balance Sheet/Tenants, And Industry Tailwinds NewLake Capital Partners, Inc. (NLCP) Q4 2025 Earnings Call Transcript NewLake Capital signals disciplined strategy and 85% payout ratio amid federal cannabis reform momentum NewLake Capital Partners GAAP EPS of $0.29, revenue of $12.3M
BYD World's most advanced power battery works with world's fastest mass-produced EV charger to make recharging as easy as refuelling 1,500kW of charging power achieves a 10%-97% refill in just nine minutes – and even in -30°C, 20%-97% takes only 12 minutes Energy-station integration opens locations to FLASH Charger Stations Plans for 20,000 chargers in China by end of 2026, plus overseas rollout S...
BYD World's most advanced power battery works with world's fastest mass-produced EV charger to make recharging as easy as refuelling 1,500kW of charging power achieves a 10%-97% refill in just nine minutes – and even in -30°C, 20%-97% takes only 12 minutes Energy-station integration opens locations to FLASH Charger Stations Plans for 20,000 chargers in China by end of 2026, plus overseas rollout SHENZHEN, China, March 09, 2026 (GLOBE NEWSWIRE) -- BYD, the world's leading manufacturer of new-energy vehicles, is ready to break down the final barriers to truly widespread adoption of EVs through its self-developed FLASH Charging, delivering up to 1500kW through a single connector, and the second generation of its iconic Blade Battery. Together, the two new technologies deliver remarkable recharging speeds, regardless of the conditions. A 10% to 70% refill takes as little as five minutes, while 10% to 97% requires only nine minutes. Even when the temperature is -30°C, conditions that would normally result in a drastic reduction in charging speeds, the FLASH Charger can take a Blade Battery 2.0 from 20% to 97% in only 12 minutes. And the Blade Battery itself is capable of longer distances on a single charge; thanks to a 5% gain in energy density, ranges of more than 1,000km are now possible (Chinese CLTC efficiency test). The new technologies are the result of intensive development by BYD, following extensive research into the barriers consumers still feel are present between them and pure-electric mobility. Despite remarkable gains in EV market penetration in most significant new-car markets worldwide, the fact remains that most buyers of pure-ICE vehicles don't pay much attention to the size of the car's fuel tank, whereas many EV customers are focused on battery capacity and range, even paying significant premiums for a few kilometres more. Wang Chuanfu, Chairman and President of BYD, emphasised today at a showcase in China that the industry needs to address the linger...
TKO Group Holdings Inc. and Polymarket signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Thursday, Nov. 13,2025. Michael Nagle | Bloomberg | Getty Images The Iran war has shone a light on what prediction markets regard as unacceptable subjects for betting, as they faced backlash when users placed hundreds of millions of wagers on everything from missile strikes to regi...
TKO Group Holdings Inc. and Polymarket signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Thursday, Nov. 13,2025. Michael Nagle | Bloomberg | Getty Images The Iran war has shone a light on what prediction markets regard as unacceptable subjects for betting, as they faced backlash when users placed hundreds of millions of wagers on everything from missile strikes to regime change. Polymarket last week archived markets that had allowed bets on the timing of a nuclear detonation, after the contracts attracted hundreds of thousands of dollars. Most of the contracts fell under a market titled "Nuclear weapon detonation by…?" that allowed users to wager on whether the event would occur by a certain date, according to webpages saved in the Internet Archive's Wayback Machine. The removal of nuclear-related markets came hours after the company reportedly posted — and later deleted — odds on X showing roughly a 22% probability of a detonation by year-end. An online outcry The bets drew outcry online and come as some makers propose tighter regulations and oversight of the fast-growing prediction industry, which allows users to bet on the outcomes of a wide range of events. Polymarket did not state the reasons for the removals. It did not immediately respond to a request for comment from CNBC. Over the weekend, the company's founder and CEO, Shayne Coplan, was asked about some of the broader controversy regarding prediction markets concerning geopolitical conflicts like Iran at the MIT Sloan Sports Analytics Conference . Coplan said it was a "complicated question," but said that prediction markets serve a powerful informational function and value proposition, including in war zones. He also dismissed some of the criticism as "more money, more problems." "There's still a lot of resistance to innovation that kind of seems jarring to begin with ... that's what makes it innovative and disruptive," he said. The Commodity Futures Trading Commission is the ...
NEW YORK (AP) — Simon & Schuster has named a former Amazon.com executive, Greg Greeley, as its new CEO. The publisher announced Monday that Greeley's appointment is effectively immediately. The 62-year-old Greeley succeeds Jonathan Karp, who announced last year that he was stepping down to head his own imprint at the company, Simon Six. Simon & Schuster, which celebrated its centennial in 1924, is...
NEW YORK (AP) — Simon & Schuster has named a former Amazon.com executive, Greg Greeley, as its new CEO. The publisher announced Monday that Greeley's appointment is effectively immediately. The 62-year-old Greeley succeeds Jonathan Karp, who announced last year that he was stepping down to head his own imprint at the company, Simon Six. Simon & Schuster, which celebrated its centennial in 1924, is home to Stephen King, Colleen Hoover and Bob Woodward and many other bestselling and prize-winning authors. While Karp is a longtime editor and publisher, Greeley has a background in business and investment. He spent nearly 20 years at Amazon, where his positions included vice president of Amazon Prime. In 2018, he left to serve as president of Airbnb's Homes division. More recently, he was president and COO of the biotechnology startup Opentrons and CEO of Thrasio, a consumer goods company. “Greg Greeley is a talented and strategic leader with wide-ranging experience managing enterprises across physical and digital markets," Richard Sarnoff, chair of the publisher's board of directors, said in a statement. “His depth of expertise and avid love of books give us the confidence that he is the right CEO to take Simon & Schuster forward as it begins its next 100 years.” Greeley will be running Simon & Schuster at a time of rapid change in the industry, with publishers, authors and agents debating the role of AI in the future of books. "Simon & Schuster has played an enduring role in sharing and shaping human culture through books, and I’m honored to steward that mission for the next generation of authors and readers,” Greeley said in a statement.
NNehring/iStock via Getty Images Albemarle Corporation ( ALB ) describes itself as "a world leader in transforming essential resources into critical ingredients for mobility, energy, connectivity and health." Founded as a stand-alone company in 1994 and headquartered in Charlotte, NC, its main business is in lithium and bromine production. It is one of the world’s largest lithium producers, contro...
NNehring/iStock via Getty Images Albemarle Corporation ( ALB ) describes itself as "a world leader in transforming essential resources into critical ingredients for mobility, energy, connectivity and health." Founded as a stand-alone company in 1994 and headquartered in Charlotte, NC, its main business is in lithium and bromine production. It is one of the world’s largest lithium producers, controlling approximately 15-20% of the global market. It independently operates two lithium brine resources, in Chile and Nevada, and jointly owns/operates two lithium hard-rock (spodumene) resources, in Greenbushes and Wodgina, Australia. These represent some of the world’s largest (1 st , 5 th and 6 th ) lithium operations in terms of planned 2026 output, as seen below. Benchmark Minerals Alongside lithium, they also operate two bromine resources, one in Arizona and a joint venture in Jordan. Adding in its various regional offices, lithium refining plants (in Chile, the U.S., Australia, and China), and production/R&D hubs, it operates in 32 locations around the world. Almost all of its buildings and sites are wholly owned by Albemarle. Albemarle Albemarle has split its business into three components: energy storage; specialties; and Ketjen. The former involves its lithium production, which includes technical and battery-grade lithium hydroxide and carbonate, lithium spodumene minerals, lithium concentrate, and lithium brine. Last year, this segment generated $2.71 billion (representing 52.7% of total sales), but 63.5% of its adjusted EBITDA. This segment carries the highest gross margins, but revenue fluctuates more wildly due to the cyclicality of lithium pricing on the global market. The specialties business is mainly focused on its bromine production and generated $1.37 billion (26.7% of sales). Last year it mined 126,000 metric tons of bromine, making Albemarle the world’s second largest producer, behind the Israeli firm ICL ( ICL ). Bromine is a critical component used in...
Monday, March 9th, 2026 “May you live in interesting times,” goes the ancient curse. We start a new week of stock market challenges sinking again in the pre-market. The ongoing war in Iran is now in its second week with no signs of a peace deal; if anything, it threatens to expand and intensify — with oil prices the initial (non-human) victim. Both WTI and Brent crude spot oil prices have spiked t...
Monday, March 9th, 2026 “May you live in interesting times,” goes the ancient curse. We start a new week of stock market challenges sinking again in the pre-market. The ongoing war in Iran is now in its second week with no signs of a peace deal; if anything, it threatens to expand and intensify — with oil prices the initial (non-human) victim. Both WTI and Brent crude spot oil prices have spiked to over $100 per barrel (/bbl), up from around $55/bbl back in December of last year. WTI oil is currently +13% to $103/bbl, Brent is +12.8%, $104.50/bbl. Oil prices are now up +78% since the start of the year. The stock market has also been victimized: the Dow is falling another -553 points at this hour, -1.16%. The S&P 500 is -71 points, -1.05%, while the Nasdaq is -281 points, -1.14%, and the small-cap Russell 2000 is down -44 points, -1.77%. Over the past month, major indexes have already fallen between -3.6% (Nasdaq) and -7.6% (Russell 2000). Good News This Morning: HIMS & Novo Make a Deal What a difference a month makes! This time, we mean it in a good way: on February 9, weight-loss drug giant Novo Nordisk NVO brought a lawsuit against health platform Hims & Hers HIMS for selling knockoff versions of its Ozempic and Wegovy weight-loss drugs. This morning, not only is Novo dropping the lawsuit, but it is partnering with Hims & Hers to sell legitimate versions of these drugs on their platform. The result is a big +54% jump in HIMS shares (NVO is up +1%), swinging the platform’s stock into positive territory after a dismal -51% start to the trading year. Considering the headwinds we are seeing in the pre-market thus far this morning, this is a most impressive performance. What to Expect from This Week’s Stock Market Aside from parsing the destruction in the Middle East, we get two major economic reports on inflation this week: Consumer Price Index (CPI) on Wednesday and Personal Consumption Expenditures (PCE) — delayed, from January — on Friday morning. CPI last reported...
Edward Morse, special advisor at Hartree Partners, says consumers should expect to see gas prices in the US top $4 a gallon soon. He also expects ships in the Strait of Hormuz to keep being attacked. In a note he says oil prices could climb another 50%. (Source: Bloomberg)
Edward Morse, special advisor at Hartree Partners, says consumers should expect to see gas prices in the US top $4 a gallon soon. He also expects ships in the Strait of Hormuz to keep being attacked. In a note he says oil prices could climb another 50%. (Source: Bloomberg)
AI infrastructure startup Nscale has raised $2 billion at a $14.6 billion valuation. But the most revealing signal about the company’s future may be the people it just added to its board When startups announce funding rounds, the headline number usually dominates the conversation. But...
AI infrastructure startup Nscale has raised $2 billion at a $14.6 billion valuation. But the most revealing signal about the company’s future may be the people it just added to its board When startups announce funding rounds, the headline number usually dominates the conversation. But...
Intel Corporation INTC is expanding its enterprise AI strategy through a deeper partnership with Infosys Limited INFY to help businesses move from AI experiments to large-scale, real-world deployments. The collaboration combines Intel’s computing infrastructure with Infosys’ AI software to speed up enterprise adoption of advanced AI solutions. Per the deal, Intel will pair its computing technologi...
Intel Corporation INTC is expanding its enterprise AI strategy through a deeper partnership with Infosys Limited INFY to help businesses move from AI experiments to large-scale, real-world deployments. The collaboration combines Intel’s computing infrastructure with Infosys’ AI software to speed up enterprise adoption of advanced AI solutions. Per the deal, Intel will pair its computing technologies with Infosys Topaz Fabric to build a flexible ecosystem that supports AI deployment from edge devices to cloud data centers. The initiative will also optimize AI workloads on Intel Xeon processors, Intel Gaudi AI accelerators, and AI-enabled PCs to help businesses run AI efficiently while balancing performance, security and cost. Through this alliance, Intel aims to enable right-sized AI infrastructure that helps enterprises deploy AI solutions aligned with their operational needs while controlling computing costs. It will also support advanced AI agents and enterprise workloads, allowing organizations to run secure, monitored and reliable AI systems in complex and regulated environments. Beyond this, Intel also launched its next-generation Panther Lake AI chip for PCs, enhancing AI performance and efficiency in personal computing. The company has also advanced AI adoption through initiatives like the AI???PC Acceleration Program and edge AI software suites, helping developers and enterprises run AI workloads more effectively. With the AI market projected to grow rapidly in the coming years, Intel is well-positioned to capitalize on this expansion by providing cutting-edge AI hardware and software solutions. Its focus on scalable, efficient and secure AI infrastructure aims to drive widespread enterprise adoption and support the next generation of AI-driven innovation. How Are Rivals Performing in the AI Space? Intel faces competition from NVIDIA Corporation NVDA and Advanced Micro Devices AMD. NVIDIA has continued to push its leadership in AI infrastructure by investing...